Гидроморфон
- английское имяHYDROMORPHONE
- CAS №466-99-9
- CBNumberCB6168696
- ФормулаC17H19NO3
- мольный вес285.34
- EINECS207-383-5
- номер MDLMFCD00864214
- файл Mol466-99-9.mol
химическое свойство
| Температура плавления | 266-267° |
| альфа | D25 -194° (c = 0.98 in dioxane) |
| Температура кипения | 427.77°C (rough estimate) |
| плотность | 1.0864 (rough estimate) |
| показатель преломления | 1.5400 (estimate) |
| Fp | 9℃ |
| температура хранения | -20°C |
| растворимость | Chloroform (Slightly), Dioxane (Slightly, Sonicated) |
| форма | Solid |
| пка | pKa 8.15 (Uncertain) |
| цвет | White to Off-White |
| Растворимость в воде | 1.931g/L(25 ºC) |
| FDA UNII | Q812464R06 |
| Словарь онкологических терминов NCI | Dilaudid |
| Словарь наркотиков NCI | Dilaudid HP |
| Код УВД | N02AA03 |
| Коды опасности | F,T | |||||||||
| Заявления о рисках | 11-23/24/25-39/23/24/25 | |||||||||
| Заявления о безопасности | 7-16-36/37-45 | |||||||||
| РИДАДР | 1544 | |||||||||
| WGK Германия | 1 | |||||||||
| Класс опасности | 6.1(a) | |||||||||
| Группа упаковки | II | |||||||||
| Банк данных об опасных веществах | 466-99-9(Hazardous Substances Data) | |||||||||
| NFPA 704: |
|
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
опасность
-
вредная бумага
H301+H311+H331：Токсично при проглатывании, при контакте с кожей или при вдыхании.
H225：Легковоспламеняющаяся жидкость. Пары образуют с воздухом взрывоопасные смеси.
H370：Поражает органы (Глаза) в результате однократного воздействия.
-
оператор предупредительных мер
P210：Беречь от тепла, горячих поверхностей, искр, открытого огня и других источников воспламенения. Не курить.
P260：Не вдыхать газ/ пары/ пыль/ аэрозоли/ дым/ туман.
P280：Использовать перчатки/ средства защиты глаз/ лица.
P301+P310：ПРИ ПРОГЛАТЫВАНИИ: Немедленно обратиться за медицинской помощью. Прополоскать рот.
P311：Обратиться за медицинской помощью.
Гидроморфон химические свойства, назначение, производство
Описание
Hydromorphone (Item No. 15463) is an analytical reference material categorized as an opioid. It is a metabolite of morphine (Item Nos. 15464 | ISO60147). Like other opioid analgesics, hydromorphone is commonly abused. Hydromorphone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.Использование
Hydromorphone, a potent opioid, is used mainly in the palliative care seing or in patients who are not opioid naive. It can be useful if considering opioid rotation. Hydromorphone 1.3mg is approximately equianalgesic to morphine 10 mg. Both immediate- and sustained-release preparations are available.Определение
ChEBI: A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.Биологические функции
Hydromorphone is eight times as potent as morphine but has less bioavailability following oral administration. Its side effects do not differ from those of morphine but are more intense. Hydromorphone is indicated for use in severe pain and in high doses for relief of pain in opioid-addicted patients.Общее описание
Hydromorphone, (Dilaudid) is a synthetic derivative ofmorphine prepared by the catalytic hydrogenation and dehydrogenationof morphine under acidic conditions, using alarge excess of platinum or palladium. Oxidation of the 6-OH of morphine resulted in a compound with decreased potency.Reducing the 7,8 double bond of morphine increasedthe flexibility of the molecule and resulted in a compoundwith slightly enhanced binding. Making both of these structuralchanges to morphine-produced hydromorphone, acompound approximately 5 times as potent as morphine.Hydromorphone was introduced in 1926 and is available as animmediate release tablet, a liquid, and a suppository. A sustainedrelease form is available in some countries but not inthe United States. The sustained release form was removedfrom the U.S. market in 2005 when studies showed that drinking8 oz of alcohol (40%) could cause the drug to be releasedfrom the capsule immediately and lead to concentrations thatwere 5.5 times higher than in patients that did not drink alcohol.This potentially lethal combination prompted the Foodand Drug Administration (FDA) to remove it from the market.